To explore potential drugs to overcome the disease progression of NSCLC patients with ARID1A deficiency, the NCI-60 database was used, and a series of small-molecule inhibitors were found to be effective (Fig. 6F). Here, ARID1A is linked to non-small cell lung carcinoma.